US 11,993,639 B2
Therapeutic IL-13 polypeptides
Kenan Christopher Garcia, Menlo Park, CA (US); and Ignacio Moraga Gonzalez, Palo Alto, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Jul. 29, 2021, as Appl. No. 17/388,895.
Application 17/388,895 is a division of application No. 16/258,420, filed on Jan. 25, 2019, granted, now 11,084,858.
Application 16/258,420 is a division of application No. 15/597,823, filed on May 17, 2017, granted, now 10,227,389, issued on Mar. 12, 2019.
Application 15/597,823 is a division of application No. 15/353,273, filed on Nov. 16, 2016, granted, now 9,732,133, issued on Aug. 15, 2017.
Application 15/353,273 is a division of application No. 14/373,498, granted, now 9,512,194, issued on Dec. 6, 2016, previously published as PCT/US2013/023194, filed on Jan. 25, 2013.
Claims priority of provisional application 61/591,781, filed on Jan. 27, 2012.
Prior Publication US 2021/0375184 A1, Dec. 2, 2021
Int. Cl. C07K 14/54 (2006.01); C07K 16/00 (2006.01); G09G 3/20 (2006.01); H04N 19/176 (2014.01); H04N 19/182 (2014.01); A61K 38/20 (2006.01)
CPC C07K 14/5437 (2013.01) [C07K 16/00 (2013.01); G09G 3/2003 (2013.01); G09G 3/2074 (2013.01); H04N 19/176 (2014.11); H04N 19/182 (2014.11); A61K 38/2086 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); G09G 2320/0247 (2013.01)] 8 Claims
 
1. A nucleic acid encoding a polypeptide, wherein the polypeptide comprises a modified interleukin 13 (IL-13) polypeptide engineered to have (a) increased affinity for interleukin 13 receptor α2 (IL-13Rα2) relative to native human IL-13 protein; and (b) decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL-13 protein; wherein the modified IL-13 polypeptide comprises amino acid changes L10H, R86T, D87G, T88R, R108K relative to wild type IL-13.